Neurocrine Biosciences (NasdaqGS:NBIX) presented new long term clinical data for CRENESSITY in classic congenital adrenal ...

Earlier in June 2026, Neurocrine Biosciences reported new Phase 3 and real‑world data at ENDO 2026 showing CRENESSITY ...

For Lower Queen Anne, the swap sets up a familiar Seattle balancing act. Neighbors and city planners will be weighing several ...

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG ...

Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S. In morning trading, the shares rose 12% ...

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy ("Duchenne" or "DMD")Fast Track is designed to expedite the development/re ...

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated sa ...

First consumer health product positions Daré for revenue generation while expanding its women's health leadership platformAccess the segment ...

Tulane University signed a purchase and sale agreement to transform the abandoned Charity Hospital into a major bioscience hub in downtown New Orleans.

The National Growth Fund will make equity investments of 500 billion won ($325 million) each in biotech firm LigaChem ...

Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

NovaBridge said the FDA granted the designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative ...